Coenzyme Q10 (Coq10) for Headache And Migraine Relief

Research suggests that CoQ10 may offer meaningful benefits for migraine prevention, with the body of evidence spanning one randomized controlled trial, multiple meta-analyses, and numerous reviews generally pointing in a supportive direction. The 2005 RCT found CoQ10 superior to placebo for reducing migraine attack frequency, headache days, and nausea, and several meta-analyses and systematic reviews from 2021 and 2025 similarly report reductions in migraine frequency, severity, and duration compared to control conditions. However, the evidence is not entirely uniform — at least two meta-analyses from 2019 returned mixed results, with one finding no significant effect on attack frequency, duration, or severity, and another finding benefits limited to headache days per month and duration but not attack frequency or severity, suggesting that the magnitude and consistency of effect remain areas of ongoing debate. Multiple clinical reviews and guidelines, including a 2012 Canadian Headache Society guideline and two independent reviews assigning Level C evidence, recognize CoQ10 as a reasonable option for migraine prophylaxis with a favorable safety profile, though the overall evidence base is constrained by the limited number of high-quality trials, underscoring the need for larger and more rigorous studies before firm conclusions can be drawn.